Press release
Gallbladder Cancer Pipeline: Advancing Innovation with 10+ Leading Companies Developing Cutting-Edge Therapies | DelveInsight
Gallbladder Cancer Pipeline
DelveInsight's "Gallbladder Cancer Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Gallbladder Cancer market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Gallbladder Cancer drugs, the Gallbladder Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Gallbladder Cancer Pipeline Report
• DelveInsight's Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline drugs for Gallbladder Cancer treatment.
• The leading Gallbladder Cancer companies include Celgene, MedImmune, Ohara Pharmaceuticals, and others are evaluating their lead assets to improve the Gallbladder Cancer treatment landscape.
• Key Gallbladder Cancer pipeline therapies in various stages of development include Zygel, BPN14770, AUT00206, Pridopidine, MG01CI, Arbaclofen, Ganaxolone, AFQ056, NNZ-2566, RO4917523, and others.
• In December 2024, Checkpoint Therapeutics, Inc. announced that the FDA approved UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.
• In December 2024, the FDA approved tislelizumab-jsgr (Tevimbra) in combination with platinum- and fluoropyrimidine-based chemotherapy for first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1.
• In December 2024, Jazz Pharmaceuticals announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for intravenous use was recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines as a category 2A treatment option for Biliary Tract Cancers (BTC).
• In April 2024, Perspective Therapeutics announced the selection of investigational product [212Pb]VMT-a-NET for the treatment of certain patients with neuroendocrine tumors by the FDA to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.
Request a sample and discover the recent breakthroughs happening in the Gallbladder Cancer pipeline landscape @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Overview
Gallbladder cancer is a rare malignancy that originates in the gallbladder, a small, pear-shaped organ located beneath the liver. The gallbladder plays a crucial role in digestion by storing bile, an enzyme produced by the liver. Most cases of gallbladder cancer arise from glandular cells lining the inner surface of the organ, a condition known as adenocarcinoma. This cancer develops due to DNA mutations in gallbladder cells, leading to abnormal and uncontrolled growth.
Gallbladder cancer is more commonly found in middle-aged women, particularly those with a history of gallstones, although it can also occur in men. The disease can present in different forms, including papillary adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma. Due to its rarity and often asymptomatic nature in the early stages, gallbladder cancer is frequently diagnosed at an advanced stage, making early detection crucial for improved outcomes.
Find out more about Gallbladder Cancer medication @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Treatment Analysis: Drug Profile
Durvalumab: Celgene
Durvalumab, developed by Celgene, is a human immunoglobulin G1 kappa monoclonal antibody currently under development for the treatment of gallbladder cancer. It works by inhibiting the immune response through blocking the interaction of PD-L1 with PD-1 and CD80. In Phase I clinical trials, the drug has shown promising efficacy and a favorable safety profile.
ONC 201: Ohara Pharmaceuticals
ONC 201, a novel drug candidate from Ohara Pharmaceuticals, is an orally administered small molecule being developed for the treatment of gallbladder cancer. It functions by inactivating the Akt/ERK signaling pathway, which leads to the upregulation of the proapoptotic immune cytokine TRAIL, promoting cancer cell death.
Key Gallbladder Cancer Therapies and Companies
• Zanidatamab: Jazz Pharmaceuticals/Zymeworks
• ENHERTU: AstraZeneca/Daiichi Sankyo
• LENVIMA: Merck Sharp & Dohme/Eisai
• Silmitasertib: CX-4945: Senhwa Biosciences
• TUKYSA: Seagen/Pfizer
• BOLD-100: Bold Therapeutics
• Tasurgratinib: Eisai
• Tinengotinib: TransThera Sciences
• Rilvegostomig: AstraZeneca/Compugen
• Durvalumab: Celgne
• ONC 201: Ohara Pharmaceuticals
Learn more about the novel and emerging Gallbladder Cancer pipeline therapies @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gallbladder Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Gallbladder Cancer Pipeline Report
• Coverage: Global
• Key Gallbladder Cancer Companies: Celgene, MedImmune, Ohara Pharmaceuticals, and others.
• Key Gallbladder Cancer Pipeline Therapies: Zygel, BPN14770, AUT00206, Pridopidine, MG01CI, Arbaclofen, Ganaxolone, AFQ056, NNZ-2566, RO4917523, and others.
Dive deep into rich insights for drugs used for Gallbladder Cancer treatment; visit @ https://www.delveinsight.com/report-store/gallbladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Gallbladder Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Gallbladder Cancer Pipeline Therapeutics
6. Gallbladder Cancer Pipeline: Late-Stage Products (Phase III)
7. Gallbladder Cancer Pipeline: Late-Stage Products (Phase III)
8. Gallbladder Cancer Pipeline: Mid-Stage Products (Phase II)
9. Gallbladder Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gallbladder Cancer Pipeline: Advancing Innovation with 10+ Leading Companies Developing Cutting-Edge Therapies | DelveInsight here
News-ID: 3954237 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Gallbladder
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Neoplasms Market Emerging Trends and Growth Prospects 2034
Introduction
Gallbladder neoplasms are rare but aggressive malignancies arising in the biliary tract, most often diagnosed at advanced stages due to their asymptomatic progression. With high mortality rates and limited curative options, gallbladder cancers represent a major clinical challenge in hepatobiliary oncology. The condition is more prevalent in certain regions such as South America, Eastern Europe, and South Asia, where genetic predisposition, gallstone disease, and chronic inflammation contribute to elevated risk.
Traditional…
Gallbladder Cancer Treatment Market Expands With Emergence of Novel Chemotherape …
Gallbladder Cancer Treatment Market Overview
The Gallbladder Cancer Treatment Market is projected to grow from USD 720 Million in 2025 to USD 1.4 Billion by 2032, at a CAGR of 10.1% during the forecast period.
Coherent Market Insights is pleased to release its latest Gallbladder Cancer Treatment Market research report, offering an in-depth analysis of the U.S. Gallbladder Cancer Treatment Market Landscape from 2025 to 2032. This report delivers reliable projections across…
Gallbladder Cancer Market to Rise by 2032 | Celgene, MedImmune, Ohara Pharmaceut …
DelveInsight's "Gallbladder Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gallbladder Cancer, historical and forecasted epidemiology as well as the Gallbladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Gallbladder Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gallbladder Cancer market size…
Gallbladder Cancer Market Size, Share Report and Forecast 2024-2032
The gallbladder cancer market size was valued at USD 87.57 million in 2023, driven by the increasing research and development activities for new treatment among people across the major markets. The market size is anticipated to grow at a CAGR of 5.56% during the forecast period of 2024-2032 to achieve a value of USD 142.5 million by 2032.
Gallbladder Cancer: Introduction
Gallbladder cancer is a rare and often aggressive malignancy that forms…
Gallbladder Cancer Therapeutics Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Gallbladder Cancer Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Gallbladder Cancer Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
